Last reviewed · How we verify
Administration of AZD6738
AZD6738 is a selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase, which plays a critical role in the DNA damage response pathway.
AZD6738 is a selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase, which plays a critical role in the DNA damage response pathway. Used for Solid tumors with defective DNA damage response pathways.
At a glance
| Generic name | Administration of AZD6738 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | ATR kinase inhibitor |
| Target | ATR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
By inhibiting ATR kinase, AZD6738 disrupts the cellular response to DNA replication stress and double-strand breaks, leading to cell cycle arrest and apoptosis in cancer cells with compromised DNA repair mechanisms.
Approved indications
- Solid tumors with defective DNA damage response pathways
Common side effects
- Nausea
- Fatigue
- Thrombocytopenia
Key clinical trials
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (PHASE2)
- A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours (PHASE1)
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer (PHASE2)
- AMTEC IIT: Phase 2 Multiarm Study in TNBC (PHASE2)
- Olaparib With Ceralasertib in Recurrent Osteosarcoma (PHASE2)
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of AZD6738 CI brief — competitive landscape report
- Administration of AZD6738 updates RSS · CI watch RSS
- AstraZeneca portfolio CI